Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D3 and the Stress-axis in MS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Relapsing Remitting MS~* At start of study \> 6 weeks in clinical remission of disease~* Age \> 18 years.~* Premenopausal~* Treated with either no immune-modulating treatment, or the currently registered MS modulating treatments: Interferon beta 1a (Rebif®), Interferon Beta 1b (Betaferon® or Avonex®), Glatiramer Acetate (Copaxone®), dimethylfumarate (Tecfidera®), teriflunomide (Aubagio®)) or fingolimod (Gilenya®).~Exclusion Criteria:~* Any contraindication to vitamin D according to Summary of Product Characteristics: Hypercalcaemia, hypervitaminosis D, nephrolithiasis, diseases or conditions resulting in hypercalcaemia and/or hypercalciuria (incl. primary hyperparathyroidism), severe renal impairment .~* Use of dexamethasone or other systemic glucocorticosteroids \<2 months prior to first study visit~* Supplementation of \>=1000 IU/d (25µg) vitamin D2 or D3~* Medical history of disturbed vitamin D/ calcium metabolism other than low intake~* Present clinical (major)depression~* Present treatment with anti-depressants, benzodiazepines, or neuroleptics.~* Treatment with high-dose dexamethasone for MS exacerbation during study.~* Pregnancy or the intention to become pregnant during the study period.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cholecalciferol (Type: EXPERIMENTAL): Patients receive 1dd 100ug vitamin D3 (drops) for 16 weeks
- Placebo comparator (Type: PLACEBO_COMPARATOR): placebo drops during 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).